Anistreplase - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Anistreplase

The Experts below are selected from a list of 747 Experts worldwide ranked by ideXlab platform

Anistreplase – Free Register to Access Experts & Abstracts

A Sacrez – One of the best experts on this subject based on the ideXlab platform.

  • invasive reperfusion study ii multicentre european randomized trial of Anistreplase vs streptokinase in acute myocardial infarction
    European Heart Journal, 1991
    Co-Authors: Gerard Pacouret, Bernard Charbonnier, N D Curien, J P Monassier, A Cribier, P Materne, M L Brochier, R Letac, M Hanssen, A Sacrez

    Abstract:

    IRS II (Invasive reperfusion study II) was a multicentre randomized trial comparing the efficacy of a 2–5-min 30 U Anistreplase intravenous injection with a 1 500 000 U 60-min streptokinase (SK) intravenous infusion in acute myocardial infarction. 116 patients were randomized within 6 h of onset of symptoms. Early coronary patency was assessable in 107 patients by coronary angiogram performed 102 min after thrombolytic treatment (range: 30–297 min) in the Anistreplase group and 93 min (range: 22–330 min) in the SK group. The early coronary patency rate was significantly higher in the Anistreplase group than in the SK group: respectively, 70% (38/54) and 51% (27/53), P<0.05. Fifty patients had assessable coronary angiograms at 90 min and 24 h. The 24-h patency rate was 92.3% (24/26) in the Anistreplase group vs 87.5% (21/24) in the SK group. No early reocclusion occurred in the Anistreplase group vs 15.4% (2/13) in the SK group (NS). Fibrinogen fell to 13.2 ±19.8% on Anistreplase vs 9.4 ±10.3% on SK (NS). Bleeding complications occurred in 12% (7/58) of treated patients in the Anistreplase group vs 20.7% (13/58) in the SK group (NS). Two cerebrovascular accidents occurred after thrombolytic treatment with Anistreplase (3.4%) vs one after SK (1.7%) (NS). Thus, Anistreplase is more effective than intravenous SK and easier to administer.

  • Invasive reperfusion study II. Multicentre European randomized trial of Anistreplase vs streptokinase in acute myocardial infarction
    European heart journal, 1991
    Co-Authors: Gerard Pacouret, Bernard Charbonnier, N D Curien, J P Monassier, A Cribier, P Materne, R Letac, M Hanssen, A Sacrez

    Abstract:

    IRS II (Invasive reperfusion study II) was a multicentre randomized trial comparing the efficacy of a 2–5-min 30 U Anistreplase intravenous injection with a 1 500 000 U 60-min streptokinase (SK) intravenous infusion in acute myocardial infarction. 116 patients were randomized within 6 h of onset of symptoms. Early coronary patency was assessable in 107 patients by coronary angiogram performed 102 min after thrombolytic treatment (range: 30–297 min) in the Anistreplase group and 93 min (range: 22–330 min) in the SK group. The early coronary patency rate was significantly higher in the Anistreplase group than in the SK group: respectively, 70% (38/54) and 51% (27/53), P

P Materne – One of the best experts on this subject based on the ideXlab platform.

  • Thrombolysis in Patients With Unstable Angina Improves the Angiographic But Not the Clinical Outcome – Results of Unasem, a Multicenter, Randomized, Placebo-controlled, Clinical-trial With Anistreplase
    Circulation, 1992
    Co-Authors: Frits W. Bär, J P Monassier, P Materne, Freek W.a. Verheugt, J. Col, P G Geslin, J. Metzger, P. Raynaud, J. Foucault, C. De Zwaan

    Abstract:

    Background. The value of thrombolytic therapy in unstable angina is unclear. Methods and Results. To study this problem, 159 patients were studied in a double-blind, placebo-controlled multicenter trial. Patients without a previous myocardial infarction, with a typical history of unstable angina, and ECG abnormalities indicative of ischemia were included. After baseline angiography, study medication (Anistreplase or placebo) was given. Angiography was repeated after 12-28 hours. A significant decrease occurred in diameter stenosis between the first and second angiogram in the Anistreplase group compared with the placebo group (11% versus 3%, p=0.008). This difference was caused by reopening of occluded vessels in the thrombolytic group. However, no beneficial clinical effects of thrombolytic treatment were found. Bleeding complications were significantly higher in patients who received thrombolytic therapy (21 versus seven patients, p=0.001). Conclusions. Thus, angiographic but no clinical improvement after thrombolytic treatment with Anistreplase was found in patients with unstable angina with an excess of bleeding complications. Therefore, thrombolytic treatment cannot be recommended in patients diagnosed as having unstable angina until proven otherwise.

  • invasive reperfusion study ii multicentre european randomized trial of Anistreplase vs streptokinase in acute myocardial infarction
    European Heart Journal, 1991
    Co-Authors: Gerard Pacouret, Bernard Charbonnier, N D Curien, J P Monassier, A Cribier, P Materne, M L Brochier, R Letac, M Hanssen, A Sacrez

    Abstract:

    IRS II (Invasive reperfusion study II) was a multicentre randomized trial comparing the efficacy of a 2–5-min 30 U Anistreplase intravenous injection with a 1 500 000 U 60-min streptokinase (SK) intravenous infusion in acute myocardial infarction. 116 patients were randomized within 6 h of onset of symptoms. Early coronary patency was assessable in 107 patients by coronary angiogram performed 102 min after thrombolytic treatment (range: 30–297 min) in the Anistreplase group and 93 min (range: 22–330 min) in the SK group. The early coronary patency rate was significantly higher in the Anistreplase group than in the SK group: respectively, 70% (38/54) and 51% (27/53), P<0.05. Fifty patients had assessable coronary angiograms at 90 min and 24 h. The 24-h patency rate was 92.3% (24/26) in the Anistreplase group vs 87.5% (21/24) in the SK group. No early reocclusion occurred in the Anistreplase group vs 15.4% (2/13) in the SK group (NS). Fibrinogen fell to 13.2 ±19.8% on Anistreplase vs 9.4 ±10.3% on SK (NS). Bleeding complications occurred in 12% (7/58) of treated patients in the Anistreplase group vs 20.7% (13/58) in the SK group (NS). Two cerebrovascular accidents occurred after thrombolytic treatment with Anistreplase (3.4%) vs one after SK (1.7%) (NS). Thus, Anistreplase is more effective than intravenous SK and easier to administer.

  • Invasive reperfusion study II. Multicentre European randomized trial of Anistreplase vs streptokinase in acute myocardial infarction
    European heart journal, 1991
    Co-Authors: Gerard Pacouret, Bernard Charbonnier, N D Curien, J P Monassier, A Cribier, P Materne, R Letac, M Hanssen, A Sacrez

    Abstract:

    IRS II (Invasive reperfusion study II) was a multicentre randomized trial comparing the efficacy of a 2–5-min 30 U Anistreplase intravenous injection with a 1 500 000 U 60-min streptokinase (SK) intravenous infusion in acute myocardial infarction. 116 patients were randomized within 6 h of onset of symptoms. Early coronary patency was assessable in 107 patients by coronary angiogram performed 102 min after thrombolytic treatment (range: 30–297 min) in the Anistreplase group and 93 min (range: 22–330 min) in the SK group. The early coronary patency rate was significantly higher in the Anistreplase group than in the SK group: respectively, 70% (38/54) and 51% (27/53), P

J P Monassier – One of the best experts on this subject based on the ideXlab platform.

  • Thrombolysis in Patients With Unstable Angina Improves the Angiographic But Not the Clinical Outcome – Results of Unasem, a Multicenter, Randomized, Placebo-controlled, Clinical-trial With Anistreplase
    Circulation, 1992
    Co-Authors: Frits W. Bär, J P Monassier, P Materne, Freek W.a. Verheugt, J. Col, P G Geslin, J. Metzger, P. Raynaud, J. Foucault, C. De Zwaan

    Abstract:

    Background. The value of thrombolytic therapy in unstable angina is unclear. Methods and Results. To study this problem, 159 patients were studied in a double-blind, placebo-controlled multicenter trial. Patients without a previous myocardial infarction, with a typical history of unstable angina, and ECG abnormalities indicative of ischemia were included. After baseline angiography, study medication (Anistreplase or placebo) was given. Angiography was repeated after 12-28 hours. A significant decrease occurred in diameter stenosis between the first and second angiogram in the Anistreplase group compared with the placebo group (11% versus 3%, p=0.008). This difference was caused by reopening of occluded vessels in the thrombolytic group. However, no beneficial clinical effects of thrombolytic treatment were found. Bleeding complications were significantly higher in patients who received thrombolytic therapy (21 versus seven patients, p=0.001). Conclusions. Thus, angiographic but no clinical improvement after thrombolytic treatment with Anistreplase was found in patients with unstable angina with an excess of bleeding complications. Therefore, thrombolytic treatment cannot be recommended in patients diagnosed as having unstable angina until proven otherwise.

  • invasive reperfusion study ii multicentre european randomized trial of Anistreplase vs streptokinase in acute myocardial infarction
    European Heart Journal, 1991
    Co-Authors: Gerard Pacouret, Bernard Charbonnier, N D Curien, J P Monassier, A Cribier, P Materne, M L Brochier, R Letac, M Hanssen, A Sacrez

    Abstract:

    IRS II (Invasive reperfusion study II) was a multicentre randomized trial comparing the efficacy of a 2–5-min 30 U Anistreplase intravenous injection with a 1 500 000 U 60-min streptokinase (SK) intravenous infusion in acute myocardial infarction. 116 patients were randomized within 6 h of onset of symptoms. Early coronary patency was assessable in 107 patients by coronary angiogram performed 102 min after thrombolytic treatment (range: 30–297 min) in the Anistreplase group and 93 min (range: 22–330 min) in the SK group. The early coronary patency rate was significantly higher in the Anistreplase group than in the SK group: respectively, 70% (38/54) and 51% (27/53), P<0.05. Fifty patients had assessable coronary angiograms at 90 min and 24 h. The 24-h patency rate was 92.3% (24/26) in the Anistreplase group vs 87.5% (21/24) in the SK group. No early reocclusion occurred in the Anistreplase group vs 15.4% (2/13) in the SK group (NS). Fibrinogen fell to 13.2 ±19.8% on Anistreplase vs 9.4 ±10.3% on SK (NS). Bleeding complications occurred in 12% (7/58) of treated patients in the Anistreplase group vs 20.7% (13/58) in the SK group (NS). Two cerebrovascular accidents occurred after thrombolytic treatment with Anistreplase (3.4%) vs one after SK (1.7%) (NS). Thus, Anistreplase is more effective than intravenous SK and easier to administer.

  • Invasive reperfusion study II. Multicentre European randomized trial of Anistreplase vs streptokinase in acute myocardial infarction
    European heart journal, 1991
    Co-Authors: Gerard Pacouret, Bernard Charbonnier, N D Curien, J P Monassier, A Cribier, P Materne, R Letac, M Hanssen, A Sacrez

    Abstract:

    IRS II (Invasive reperfusion study II) was a multicentre randomized trial comparing the efficacy of a 2–5-min 30 U Anistreplase intravenous injection with a 1 500 000 U 60-min streptokinase (SK) intravenous infusion in acute myocardial infarction. 116 patients were randomized within 6 h of onset of symptoms. Early coronary patency was assessable in 107 patients by coronary angiogram performed 102 min after thrombolytic treatment (range: 30–297 min) in the Anistreplase group and 93 min (range: 22–330 min) in the SK group. The early coronary patency rate was significantly higher in the Anistreplase group than in the SK group: respectively, 70% (38/54) and 51% (27/53), P